{"entity":{"id":"lu-shun","kind":"person","name":"Shun Lu","aka":["shun-lu"],"tldr":"A Shanghai lung cancer trialist who has led many Chinese PD-1 and EGFR-TKI phase 3 studies.","summary":"Shun Lu is Professor and Director of the Shanghai Lung Cancer Center at Shanghai Chest Hospital and a leader of the Chinese Thoracic Oncology Group. He has been principal investigator for many Chinese phase 3 trials, including sintilimab and tislelizumab combinations in non-small-cell lung cancer and studies of furmonertinib and other EGFR inhibitors. His publications include the AENEAS trial of aumolertinib against gefitinib as first-line therapy for EGFR-mutated lung cancer, the trial of osimertinib after chemoradiotherapy in stage III EGFR-mutated disease, and the LUX-Lung 7 comparison of afatinib and gefitinib. His interests are immunotherapy, EGFR tyrosine kinase inhibitors and clinical trials. He has also co-authored global registrational trials of targeted therapy and immunotherapy, including ADAURA, CheckMate 816 and MARIPOSA, and his work has shaped EGFR- and ALK-directed treatment in East Asian populations.","asOf":"2026-09-08","links":[{"label":"Shanghai Chest Hospital","url":"https://www.shxkyy.com"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20S%5BAuthor%5D%20Shanghai%20Chest%20Hospital%20lung%20cancer"}],"tags":["clinician-scientist","lung cancer","targeted therapy"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":["egfr","pd1"],"drugs":["tislelizumab"],"companies":["ctong"],"institutions":["shanghai-chest-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor; Director, Shanghai Lung Cancer Center, Shanghai Chest Hospital","institutionId":"shanghai-chest-hospital","specialisms":["Lung cancer","Immunotherapy","EGFR-TKIs","Clinical trials","Targeted therapy"],"profiles":[{"label":"Shanghai Chest Hospital","url":"https://www.shxkyy.com"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20S%5BAuthor%5D%20Shanghai%20Chest%20Hospital%20lung%20cancer"}],"papers":[{"title":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.02641"},{"title":"Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC","journal":"New England Journal of Medicine","year":2024,"doi":"10.1056/nejmoa2402614"},{"title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30033-x"},{"title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2020,"doi":"10.1056/NEJMoa2027071"},{"title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","journal":"New England Journal of Medicine","year":2022,"doi":"10.1056/NEJMoa2202170"},{"title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","journal":"New England Journal of Medicine","year":2024,"doi":"10.1056/NEJMoa2403614"}],"orcid":"0000-0001-8833-7262"},"route":"/people/lu-shun/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"ctong","kind":"company","name":"Chinese Thoracic Oncology Group","route":"/companies/ctong/"}],"institution":[{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/"}],"paper":[{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/"},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/"},{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/"},{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/"},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/"}],"trial":[{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/"}]}}